Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis

MLA

Dan Liu, et al. “Comparison of CAR T-Cell and Bispecific Antibody as Third-Line or Later-Line Treatments for Multiple Myeloma: A Meta-Analysis.” Journal for ImmunoTherapy of Cancer, vol. 12, no. 11, Nov. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2024-010064.

APA

Dan Liu, Liang Wang, Xiaojie Liang, Yufan Wang, Baiwei Luo, Bingyu Lin, WeiXiang Lu, & Shengyu Tian. (2024). Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. Journal for ImmunoTherapy of Cancer, 12(11). https://doi.org/10.1136/jitc-2024-010064

Chicago

Dan Liu, Liang Wang, Xiaojie Liang, Yufan Wang, Baiwei Luo, Bingyu Lin, WeiXiang Lu, and Shengyu Tian. 2024. “Comparison of CAR T-Cell and Bispecific Antibody as Third-Line or Later-Line Treatments for Multiple Myeloma: A Meta-Analysis.” Journal for ImmunoTherapy of Cancer 12 (11). doi:10.1136/jitc-2024-010064.